drugset

drugset / Trial / NCT06329258

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258 ↗

Phase 4 Completed 30 enrolled Psoriasis Treatment Center of Central New Jersey

Non-randomizedSingle-groupOpen-labelTreatment

Summary

combination deucravacitinib and enstilar foam

Timeline

Start: 2022-12-06
Primary completion: 2023-11-13
Completion: 2023-11-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	6 mg	—
Subject	Enstilar	Unknown	0.005 %	Topical
Subject	Enstilar	Unknown	0.064 %	Topical

Indications